- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03751098
Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation (MIST-2)
March 16, 2022 updated by: Eyenovia Inc.
A Multi-Center, Double-Masked, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Fixed Combination Phenylephrine 2.5%-Tropicamide 1% Ophthalmic Solution Administered With a Microdose Dispenser for Dilation of the Pupil
This study evaluated pupil dilation after administration of fixed combination tropicamide-phenylephrine (TR/PH) vs. placebo.
Participants attended 3 visits.
At each visit, after baseline measurements, either the study drug or placebo was administered to both eyes, then pupil dilation and safety assessments were performed at specific time intervals.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Volunteer participants were screened for study eligibility during a Screening Visit and enrolled after signing the study-specific informed consent form.
Subjects meeting all inclusion/exclusion criteria were scheduled for 3 treatment visits, which were at least 2 days, but no more than 7 days apart.
At each treatment visit, baseline measurements were taken, then either the study drug or placebo was administered to both eyes.
Afterwards, efficacy and safety assessments were performed at 20, 35, 50, 65, 80, 120, and 180 minutes.
Participants' treatment assignments for each treatment visit were equally randomized using 1 of 2 sequences - ABB or BAA, where A was the study drug and B was the placebo.
Study Type
Interventional
Enrollment (Actual)
76
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Austin, Texas, United States, 78731
- Keystone Research
-
San Antonio, Texas, United States, 78229
- R&R Research
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Ability to provide written consent and return for all study visits
- Photopic pupil diameter <= 3.5 mm in each eye
Exclusion Criteria:
- Allergy to phenylephrine hydrochloride, tropicamide, or benzalkonium chloride
- History of benign prostatic hyperplasia
- Use of a benzodiazepine, monoamine oxidase inhibitor, tricyclic antidepressant, anticonvulsant, or cholinergic drug
- History of closed-angle glaucoma
- Anatomically narrow anterior chamber angles
- Ocular surgery or laser treatment of any kind
- History of chronic or acute uveitis
- History of traumatic iritis or hyphema
- History of traumatic mydriasis or angle recession
- History of heterochromia
- Irregularly-shaped pupil secondary to ocular trauma or congenital defect.
- History of neurogenic pupil disorder
- History of anterior chamber intraocular lens (IOL) or iris-fixated IOL
- History of iris surgery, iris atrophy, or iris-cornea apposition/touch
- Unwilling or unable to discontinue use of contact lenses at treatment visits.
- Current active eye disease for which topical or systemic ophthalmic medication is necessary, except for dry eye disease managed using artificial tears.
- Presence of a severe/serious ocular condition, or any other unstable medical condition that, in the Investigator's opinion, may preclude study treatment and/or follow-up
- Pregnancy or lactation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: 1-TR/PE, 2-Placebo, 3-Placebo
Participants were dosed once at 3 separate clinic visits in accordance with this sequence.
Each participant received 2 sprays of the designated treatment in each eye.
|
Tropicamide 1%/phenylephrine 2.5% ophthalmic solution administered with the Optejet microdose dispenser
Other Names:
Eyewash administered with the Optejet microdose dispenser
|
OTHER: 1-Placebo, 2-Placebo, 3-TR/PE
Participants were dosed once at 3 separate clinic visits in accordance with this sequence.
Each participant received 2 sprays of the designated treatment in each eye.
|
Tropicamide 1%/phenylephrine 2.5% ophthalmic solution administered with the Optejet microdose dispenser
Other Names:
Eyewash administered with the Optejet microdose dispenser
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Pupil Diameter From Baseline
Time Frame: 35 minutes after initial dose
|
Difference in 35-minute pupil diameter vs. baseline measured using pupillometry in highly photopic conditions. Pupil diameter is reported in millimeters. For the change in pupil diameter, larger measurements indicate a better outcome. |
35 minutes after initial dose
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of Eyes Achieving Pupil Diameter 6.0 mm or Larger After Receipt of Each Medication
Time Frame: 35 minutes after initial dose
|
The percent of eyes with pupil diameter 6.0 mm or larger as measured using pupillometry in highly photopic conditions.
As this is a cross-over study, each of the 69 participants received each medication.
Data is reported separately for the right and left eyes of the 69 participants.
A higher percentage indicates a better outcome.
|
35 minutes after initial dose
|
Proportion of Eyes Achieving Pupil Diameter 7.0 mm or Larger After Receipt of Each Medication
Time Frame: 35 minutes after initial dose
|
The percent of eyes with pupil diameter 7.0 mm or larger as measured using pupillometry in highly photopic conditions.
As this is a cross-over study, each of the 69 participants received each solution.
Data is reported separately for the right and left eyes of the 69 participants.
A higher percentage indicates a better outcome.
|
35 minutes after initial dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
December 1, 2018
Primary Completion (ACTUAL)
January 21, 2019
Study Completion (ACTUAL)
January 21, 2019
Study Registration Dates
First Submitted
November 14, 2018
First Submitted That Met QC Criteria
November 20, 2018
First Posted (ACTUAL)
November 23, 2018
Study Record Updates
Last Update Posted (ACTUAL)
March 18, 2022
Last Update Submitted That Met QC Criteria
March 16, 2022
Last Verified
January 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Eye Diseases
- Pupil Disorders
- Mydriasis
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Muscarinic Antagonists
- Cholinergic Antagonists
- Cholinergic Agents
- Protective Agents
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Cardiotonic Agents
- Respiratory System Agents
- Pharmaceutical Solutions
- Sympathomimetics
- Vasoconstrictor Agents
- Mydriatics
- Nasal Decongestants
- Adrenergic alpha-1 Receptor Agonists
- Ophthalmic Solutions
- Phenylephrine
- Oxymetazoline
- Tropicamide
Other Study ID Numbers
- EYN-MYD-TP-32
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mydriasis
-
Eyenovia Inc.Completed
-
Johns Hopkins UniversityTerminated
-
University Hospital, AntwerpCompleted
-
Eyenovia Inc.Completed
-
Eyenovia Inc.CompletedMydriasisUnited States
-
Eyenovia Inc.Completed
-
Medical University of GrazCompleted
-
Changzhou Second People's Hospital affiliated with...RecruitingAphakia | MydriasisChina
Clinical Trials on Tropicamide/Phenylephrine ophthalmic solution (TR/PE)
-
Eyenovia Inc.Completed
-
Eyenovia Inc.Completed
-
Eyenovia Inc.CompletedMydriasisUnited States
-
Assistance Publique - Hôpitaux de ParisIoltechTerminatedPremature Birth | Retinal AnomaliesFrance
-
Johnson & Johnson Consumer and Personal Products...Completed
-
RVL Pharmaceuticals, Inc.Completed
-
RVL Pharmaceuticals, Inc.CompletedAcquired BlepharoptosisUnited States
-
Wake Forest University Health SciencesCompleted
-
University of MiamiCompletedEye Manifestations | Ptosis, Eyelid | Conjunctiva InflamedUnited States
-
Laboratorios PoenCompleted